(19)
(11) EP 2 626 418 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.03.2021 Bulletin 2021/12

(45) Mention of the grant of the patent:
09.12.2020 Bulletin 2020/50

(21) Application number: 11830662.0

(22) Date of filing: 04.10.2011
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
A61P 37/04(2006.01)
C07K 14/82(2006.01)
A61P 35/00(2006.01)
 A61K 35/17(2015.01)
A61P 43/00(2006.01)
C12N 5/0783(2010.01)
(86) International application number:
PCT/JP2011/072874
(87) International publication number:
WO 2012/046730 (12.04.2012 Gazette 2012/15)

(54)

METHOD FOR ACTIVATING HELPER T CELL

VERFAHREN ZUR AKTIVIERUNG VON T-HELFERZELLEN

PROCÉDÉ D'ACTIVATION D'UNE CELLULE T AUXILIAIRE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 05.10.2010 JP 2010225806

(43) Date of publication of application:
14.08.2013 Bulletin 2013/33

(73) Proprietor: International Institute of Cancer Immunology, Inc.
Suita-shi, Osaka 564-0053 (JP)

(72) Inventors:
  • SUGIYAMA, Haruo
    Minoo-shi Osaka 562-0036 (JP)
  • SOGO, Shinji
    Osaka-shi Osaka 541-0045 (JP)
  • SATO, Masayoshi
    Osaka-shi Osaka 541-0045 (JP)
  • KITAMOTO, Ryuki
    Osaka-shi Osaka 541-0045 (JP)
  • GOTO, Yoshihiro
    Osaka-shi Osaka 541-0045 (JP)

(74) Representative: dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB 
Deichmannhaus am Dom Bahnhofsvorplatz 1
50667 Köln
50667 Köln (DE)


(56) References cited: : 
EP-A1- 1 696 027
EP-A1- 2 119 778
WO-A1-2008/105462
 EP-A1- 2 098 595
WO-A1-2005/045027
WO-A1-2010/123065
   
  • MAY RENA J ET AL: "Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 15 Pt 1, 1 August 2007 (2007-08-01), pages 4547-4555, XP002544528, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-0708
  • C. LEHE ET AL: "The Wilms' Tumor Antigen Is a Novel Target for Human CD4+ Regulatory T Cells: Implications for Immunotherapy", CANCER RESEARCH, vol. 68, no. 15, 1 August 2008 (2008-08-01), pages 6350-6359, XP055082460, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-0050
  • FUJIKI F ET AL: "A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells", MICROBIOLOGY AND IMMUNOLOGY, CENTER FOR ACADEMIC PUBLICATIONS JAPAN , JP, vol. 52, no. 12, 1 December 2008 (2008-12-01), pages 591-600, XP002590600, ISSN: 0385-5600, DOI: 10.1111/J.1348-0421.2008.00080.X
  • MUELLER L ET AL: "SYNTHETIC PEPTIDES DERIVED FROM THE WILMS' TUMOR 1 PROTEIN SENSITIZE HUMAN T LYMPHOCYTES TO RECOGNIZE CHRONIC MYELOGENOUS LEUKEMIA CELLS", HEMATOLOGY JOURNAL, MCMILLAN, BASINGSTOKE, GB, vol. 4, no. 1, 1 January 2003 (2003-01-01) , pages 57-66, XP009044674, ISSN: 1466-4860, DOI: 10.1038/SJ.THJ.6200220
  • KNIGHTS ASHLEY JOHN ET AL: "Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 51, no. 5, 1 July 2002 (2002-07-01), pages 271-281, XP002473128, ISSN: 0340-7004, DOI: 10.1007/S00262-002-0278-2
  • MAY R.J. ET AL.: 'Peptide epitopes from the Wilms' Tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells' CLIN CANCER RES. vol. 13, no. 15, 2007, pages 4547 - 4555, XP002544528
  • FUJIKI F. ET AL.: 'A WT1 protein-derived, naturally processed 16-mer peptide, WT1322, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells' MICROBIOL. IMMUNOL. vol. 52, 2008, pages 591 - 600, XP002590600
  • LEHE C. ET AL.: 'The Wilms' Tumor antigen is a novel target for human CD4+ regulatory T cells : Implications for immunotherapy' CANCER RES. vol. 68, 2008, pages 6350 - 6359, XP055082460
  • KNIGHTS A.J. ET AL.: 'Prediction of an HLA-DR-binding peptide derived from Wilms' tumor 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol' CANCER IMMUNOL. IMMUNOTHER. vol. 51, 2002, pages 271 - 281, XP002473128
  • MULLER L. ET AL.: 'Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells' HEMATOL.J. vol. 4, no. 1, 2003, pages 57 - 66, XP009044674
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).